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Abstract
Background: Effective case management is central to reducing malaria mortality and morbidity worldwide, but only a minority
of those affected by malaria, have access to prompt effective treatment.
In Kenya, the Division of Malaria Control is committed to ensuring that 80 percent of childhood fevers are treated with effective
anti-malarial medicines within 24 hours of fever onset, but this target is largely unmet. This review aimed to document evidence
on access to effective malaria treatment in Kenya, identify factors that influence access, and make recommendations on how to
improve prompt access to effective malaria treatment. Since treatment-seeking patterns for malaria are similar in many settings
in sub-Saharan Africa, the findings presented in this review have important lessons for other malaria endemic countries.
Methods: Internet searches were conducted in PUBMED (MEDLINE) and HINARI databases using specific search terms and
strategies. Grey literature was obtained by soliciting reports from individual researchers working in the treatment-seeking field,
from websites of major organizations involved in malaria control and from international reports.
Results: The review indicated that malaria treatment-seeking occurs mostly in the informal sector; that most fevers are treated,
but treatment is often ineffective. Irrational drug use was identified as a problem in most studies, but determinants of this
behaviour were not documented. Availability of non-recommended medicines over-the-counter and the presence of
substandard anti-malarials in the market are well documented. Demand side determinants of access include perception of illness
causes, severity and timing of treatment, perceptions of treatment efficacy, simplicity of regimens and ability to pay. Supply side
determinants include distance to health facilities, availability of medicines, prescribing and dispensing practices and quality of
medicines. Policy level factors are around the complexity and unclear messages regarding drug policy changes.
Conclusion: Kenya, like many other African countries, is still far from achieving the Abuja targets. The government, with
support from donors, should invest adequately in mechanisms that promote access to effective treatment. Such approaches
should focus on factors influencing multiple dimensions of access and will require the cooperation of all stakeholders working
in malaria control.
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Background
Effective case management is central to reducing malaria
mortality and morbidity worldwide. In the Abuja declara-
tion of 2000, African heads of state committed themselves
to ensure that 60 percent of childhood fevers are treated
with effective anti-malarial medicines within 24 hours of
symptom onset, a target that has since been increased to
80 percent by 2010 [1]. In Kenya, the Ministry of Health,
together with the Division of Malaria Control (DOMC)
are committed to achieving the Abuja targets, embedded
within the strategic approaches of the National Malaria
Strategy [2]. Together with partners, the DOMC have been
monitoring progress toward these targets using both sen-
tinel sites and national surveys.
Kenya has a multi-pronged malaria control strategy,
through which the country has introduced artemisinin-
based combination therapy (ACT) as the first-line drug
[2,3], and dramatically increased the use of insecticide-
treated nets among children under five [4]. Detailed
guidelines for malaria case management were developed
following the policy change from sulphadoxine-
pyrimethamine (SP) to artemether-lumefantrine (AL).
The World Health Organization (WHO) highlights the
need to ensure access to and rational use of ACT, not only
because ACT is more effective in case management, but
also because irrational drug use could lead to drug resist-
ance [5]. A summary of Kenya's treatment policy is pro-
vided in Table 1.
Several initiatives have been implemented over the years
to improve access to malaria treatment, including
strengthening home management of fevers by training
private medicine retailers on effective case management
[6-10]; engaging community health workers to dispense
anti-malarials [11-13]; and training health workers to
diagnose and prescribe anti-malarials appropriately
[14,15]. Some of these interventions have been shown to
be effective [16], but their sustainability remains
unknown. In an attempt to improve access to malaria
treatment, the Kenyan government changed the charging
policy at all public dispensaries and health centres in July
2004. User fees were abolished under the new policy and
a flat registration fees introduced of Kenya Shillings (KES)
10 and KES 20 respectively (approximately 2008 USD 0.2
and 0.3 respectively). Children aged below five years and
Table 1: Kenya's Current Malaria Treatment Policy
Condition Recommendation Dosage Form Strength
Uncomplicated malaria 
(First-line treatment)
Artemether-lumefantrine Tablet 20 mg Artemether + 120 mg 
Lumefantrine
Uncomplicated malaria 
(Second-line treatment)
Quinine Tablet 200 mg
300 mg
Severe and complicated malaria
Pre-referral treatment Artemether injection Injection Adult: 80 mg/ml
Pediatric: 20 mg/ml
Artesunate injection Injection 60 mg/1 ml ampoule
Artesunate rectal caps Suppositories 100 mg
400 mg
IV/IM phase Quinine Injection (IV or IM) 300 mg/1 ml ampoule
600 mg/2 ml ampoule
Continuation phase Quinine Tablet 200 mg
300 mg
Prevention of malaria in pregnancy Intermittent Preventive Treatment 
(IPTp) using SP
Tablet Sulphadoxine 500 mg; Pyrimethamine 
25 mg
Treatment of uncomplicated malaria 
in pregnancy
Trimester 1: Quinine Tablet 300 mg
Trimester 2 & 3: Quinine or Tablet 300 mg
Artemether-Lumefantrine Tablet 20 mg Artemether + 120 mg 
Lumefantrine
Treatment of complicated malaria in 
pregnancy
The treatment of pregnant women with severe malaria shall be the same as the treatment of severe 
malaria in the general population.
(Source: DOMC 2006)Malaria Journal 2009, 8:243 http://www.malariajournal.com/content/8/1/243
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specific health conditions such as malaria were exempted
from paying the registration fees. An evaluation of this
policy showed that these changes were not fully imple-
mented, and individuals suffering from malaria contin-
ued to pay the registration fees [17].
Although data on access to malaria treatment in Kenya is
scanty, the majority of ill individuals, especially the poor,
do not have access to prompt effective treatment [18].
Information on the factors that hinder people from seek-
ing treatment promptly is lacking. While several studies
have focused on treatment-seeking behaviour, there has
been no attempt to synthesize existing data, or to create a
comprehensive overview of the current access situation in
Kenya. This paper seeks to document the evidence on
access to effective malaria treatment in Kenya, identify fac-
tors that influence access, and identify gaps that should be
addressed to improve prompt access to effective malaria
treatment. Although the paper presents evidence from
Kenya, the lessons learnt are useful for other malaria
endemic countries in sub-Saharan Africa.
Defining access
Most studies on access to malaria treatment focus on the
ability to acquire anti-malarials and utilization of health
care services. Yet access to prompt effective treatment is
broader than utilization of services, and or being able to
acquire anti-malarials. In this review, access is presented
as a multifaceted issue, influenced by many interrelated
factors occurring at the demand, supply, and policy level.
Access comprises four main dimensions namely [19-22]:
(1) availability, referring to the geographical location of
health care services in relation to the clients; (2) afforda-
bility, which includes the costs of seeking care and ability
to cope; (3) acceptability, referring to the nature of service
provision and how individuals and communities perceive
them and; (4) adequacy, which includes the extent to
which the organization of health care meets client's expec-
tation. To understand access and to be able to draw con-
crete and actionable policy recommendations, all
elements of access should be considered comprehen-
sively.
Methods
Search strategy
PUBMED (MEDLINE) and HINARI were the main data
bases used to retrieve papers included in this review. A
summary of the search terms and strategies applied is pro-
vided in Figure 1. For unpublished data, individual
researchers were contacted and reference lists of all studies
retrieved, checked to identify any other relevant work.
Websites of organizations working in malaria control,
such as the DOMC, WHO, Management Sciences for
Health and websites that aggregate information (for
example, Eldis and ID21) were also included. Key varia-
bles of interest to the review included sources of treat-
ment, types of medicines used to treat malaria, timing of
treatment, costs of treatment, and determinants of access.
Description of studies included in the review
A total of 39 articles were reviewed. The studies applied
different methodologies and investigated different varia-
bles of interest making it difficult to arrive at a strict inclu-
sion/exclusion criterion as would be expected in a
systematic review. Consequently, the review included any
study that focused on at least one variable related to any
of the dimensions of access defined earlier. The majority
of studies (n = 28) were carried out in rural districts; four
were carried out in both rural and urban settings; and the
remaining studies were desk reviews of malaria treatment
policies. Sixteen studies focused on children as their pop-
ulation of interest. Most of the studies were quantitative;
only three studies incorporated a qualitative component.
The studies differed in methodology including cross-sec-
tional surveys, longitudinal surveys, panel surveys, inter-
ventions, and desk reviews. They also differed in terms of
when they were conducted: 10 were conducted before
1998 when the first line drug was chloroquine (n = 10);
20 we conducted between 1999 to 2005 when SP was the
drug of choice, and only nine were conducted after 2006,
the year that the government changed the treatment pol-
icy from SP to AL.
Studies explored various variables of interest ranging from
physical access to clinical services, quality of pediatric case
management, cost of malaria treatment, malaria manage-
ment practices at hospitals, malaria diagnostic practices,
and medicine dispensing practices. Most studies were not
designed specifically to understand access, but they pro-
vided useful information on key variables of interest. The
majority of studies (n = 25) were conducted at the com-
munity level.
Studies included in this review define malaria differently.
While most studies used self-reported fever to indicate
malaria, others tested for the presence of parasites, while
others did not provide any information on how malaria
was defined. For the purposes of this review all relevant
studies were included, irrespective of how malaria was
defined. The terms fever and malaria are used inter-
changeably.
Results
Sources of treatment
Several studies documented the pattern of treatment-seek-
ing for malaria. The results indicated that treatment
sources included both the formal and the informal sec-
tors, with a few fevers left untreated. Drawing a line
between the formal and informal sector is difficult due to
the heterogeneity of services provided, and the nature ofMalaria Journal 2009, 8:243 http://www.malariajournal.com/content/8/1/243
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regulatory systems, that do not always provide a clear cut
view in terms of what is formal or not [23]. For opera-
tional purposes in this review, the formal sector refers to
the use of both private and public health care providers
including dispensaries, health centres, clinics and hospi-
tals. It involves consulting a health provider for illness
diagnosis and treatment. The informal sector refers to the
use of drug sellers (particularly shops) that do not require
a licence to sell over-the-counter (OTC) drugs, although
they may sell prescription drugs illegally. Drug sellers do
not always provide professional consultation because
they may not have appropriate training or qualifications.
The informal sector also includes community health
workers and traditional healers.
The proportions of fevers not receiving any type of treat-
ment ranged from none [24] to 25 percent [25]. In gen-
eral, treatment-seeking patterns were similar across
settings and age groups, although children were more
likely than adults to be treated by formal health providers,
because malaria is perceived to be more severe in the
former [26]. The main types of treatment included: self-
treatment using drugs bought from private sector shops or
left-over drugs from a previous illness episode, treatment
received at private and public health facilities, traditional
remedies taken at home, and use of traditional healers.
Table 2 summarizes the proportion of fevers treated
through different sources of treatment, while Table 3
presents a summary of the sources of first actions for
fevers. Most fevers were treated by adopting only one
action. For example, in Gucha and Kisumu districts, 87
and 75 percent of all fevers, respectively, were treated with
one action [27,28], while only nine percent of fevers in
Kilifi district were treated using more than two actions
[11]. A few studies reported the use of multiple treat-
ments, with a typical pattern of self-treatment, followed
by a visit to a health facility or traditional healer
[24,26,28-31].
Self-treatment using OTC drugs was the most common
first action taken in response to malaria [18,24,26-32].
The results from different parts of the country show that
the proportion of fevers first treated at home was high, but
considerable variations existed between settings. In Kisii
district, for example, the proportion of fevers first treated
using drugs at home was 83 percent [24], while in Baringo
district, only five percent of first actions involved self-
treatment [33].
Use of the formal sector as a first source of treatment for
malaria was less common, often comprising less than half
of all actions [18,24,26,27,30,31,34]. A few studies have
reported the formal sector as the main source of treat-
ment, although the percentage of fevers that were first
treated in the formal sector was low [35,36].
Types of anti-malarial medicines used
The type of medicines normally taken to treat fevers was
hardly documented in the studies reviewed. The few that
classified the medicines taken reported that collecting
these data was difficult due to the wide range of anti-
malarial brands and other medicines in the market (for
those self-treating), and because people do not always
know the type of drugs they receive at health facilities
[37]. Moreover, medicines in public health facilities are
unlabeled and are normally dispensed from unlabeled
containers, which makes it difficult for researchers to cat-
egorize the drugs during data collection [38].
Table 4 shows that the proportion of fevers treated using
anti-malarials ranged from 23 percent [6] to 91 percent
[39]. The proportion of fevers treated with government-
recommended anti-malarials was much lower in all sec-
tors, although people seeking treatment from the formal
sector were more likely to receive the recommended anti-
malarials than those in the informal sector. Overall, indi-
viduals who self-treat malaria use antipyretics more often
[26,30,31,36,40-43]. A nationally representative survey
reported that only 28 percent of children with fevers took
anti-malarials. Of those children that received anti-malar-
ials, 11 percent took SP, the nationally recommended
drug at the time; 10 percent took amodiaquine, and three
percent took quinine [40]. In Gucha district, only one-
third of individuals reporting a fever received anti-malari-
als as part of home-based treatment, but only 27 percent
of them took SP, the recommended treatment at the time
[27]. In 2002/2003, the proportion of fevers receiving SP
Key words used for the review Figure 1
Key words used for the review.Malaria Journal 2009, 8:243 http://www.malariajournal.com/content/8/1/243
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in public outpatient departments was estimated as 67 per-
cent. Of these, 84 percent received the nationally recom-
mended dose [39]. A recent longitudinal study found that
amodiaquine was the most commonly used anti-malarial
in both the formal and informal sectors, and although 31
percent of fevers were treated with anti-malarials at some
point, only 10 percent were treated with AL, 95 percent of
which was obtained from the formal sector [44].
Adherence to treatment
Assessment of treatment adherence was limited because
very few studies provided data on use of medicines, and
none were specifically designed to measure drug adher-
ence. Nevertheless, the results indicated that inappropri-
ate use of medicines was common among individuals
using both the formal and the informal sector. In Western
Kenya, for example, the appropriate use of drugs was only
reported in 12 percent of patients treated at home, while
in Kilifi and Malindi districts, only two percent of children
given chloroquine bought from shops received an ade-
quate dose [45]. Bungoma district also reported high lev-
els of non-adherence, where despite 43 percent of ill
children being treated at a health facility, 58 percent of
caretakers stopped treatment after the children showed
signs of recovery [25]. Elsewhere, 55 percent of mothers
who received anti-malarials at health facilities did not fol-
low instructions on how to use the medication, and none
asked for clarification because they feared the health
workers [30]. While none of the reviewed studies docu-
mented levels of adherence to AL in Kenya, the high level
of non-adherence to previous anti-malarials suggests that
adherence to ACT is also likely to be poor because of com-
plex dosage patterns and the comparatively high cost. One
of the few studies exploring adherence to ACT in sub-
Saharan Africa reported 61 percent non-adherence among
children receiving ACT in a health facility, and about 40
percent of the caretakers could not state the correct dosage
for the medicine moments after they had received the
drugs from the pharmacy [46]. Children whose parents
had received some education and caretakers who spoke
the same native language as the pharmacist were signifi-
cantly more adherent.
Timing and cost of malaria treatment to households
The timing of treatment is an important factor in manag-
ing malaria effectively. Table 5 provides a summary of the
number of days taken before seeking treatment. Overall,
the results reveal that delaying treatment was common;
only a few cases were treated within the recommended
first 24 hours; and that the number of days taken before
seeking treatment differs by treatment source. A median
delay of two days was reported, with only five percent of
fevers treated with anti-malarials within the first 24 hours
[36]. The number of days taken before seeking treatment
in the formal sector was higher, with most people contact-
ing the formal sector after 48 hours [11,25,26,30]. Indi-
viduals who self-treated were more likely to take
medicines within the first 24 hours of symptom onset
compared to those who sought treatment from the formal
sector [18,25,28,31,43].
Regarding costs, few studies estimated the costs of malaria
treatment to households or to the health system. Compar-
ing findings from the studies identified posed a challenge
due to methodological differences in valuing costs and the
variables explored. However, the results indicated that
households spent a significant amount of money on
malaria treatment. In Rusinga Island, the median expend-
Table 2: Summary of treatment-seeking patterns as reported in 
different settings
Reference Formal Informal Traditional
Treatment-seeking patterns as % of all treated fevers
[7] (Children) 47 53 N/A*
[7] (Adults) 57 43 N/A
[37] 54 46 N/A
[45] 35 62 1
[27] 30 47 12
[34] 74 5 N/A
[44] 28 64 N/A
[29] 16 75 10
Treatment-seeking patterns as % of all reported fevers
[37] 39 46 N/A
[36] 59 17 4
[28] 26 47 N/A
[26] 43 47 N/A
38 30 32
[30] 30 32 25
[35] 55 32 7
[31] 25 59 7
[25] 14.3 83 3
[48] 44 55 N/A
*N/A = information not available.Malaria Journal 2009, 8:243 http://www.malariajournal.com/content/8/1/243
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iture for treating sick children with malaria was estimated
as US$ 3.1 [47], while mean treatment costs were esti-
mated as US$ 0.3 for the first action and US$ 0.1 for the
second action in western Kenya [28]. Mean spending for
an acute malaria episode amounted to US$ 3 [18]. Drug
costs comprised the largest share of over 80 percent in all
studies, while transport costs were relatively low.
A study that estimated the median cost of drugs for one
treatment purchased in retail outlets reported a mean cost
of US$ 0.2, while the median cost of drugs for one treat-
ment from a private hospital was US$ 3 [36]. The average
retail price of adult doses of SP and amodiaquine pur-
chased from the Kenyan retail sector was estimated as US$
0.4 and US$ 1 respectively [48], while the median cost of
AL was US$ 11. Direct cash expenditure per fever was esti-
mated at $ 0.4, and a total cost of US$ 2 (including direct
costs) for uncomplicated fevers treated according to the
national guidelines i.e. prompt treatment with AL. It is
worth noting that the average costs to households of treat-
ing malaria are likely to increase substantially if AL is
availed in the informal retail sector.
Factors influencing access to prompt effective treatment
Although a number of studies reported on factors influ-
encing access to malaria treatment, access was not their
primary focus. Of the studies reviewed, only one study
was specifically designed to understand barriers to access.
A variety of interrelated factors affect prompt and effective
treatment of malaria. They include demand, supply and
policy-level determinants.
Demand-side determinants
Demand-side determinants refer to factors at the individ-
ual and household level that influence the ability to initi-
ate and successfully complete appropriate malaria
treatment. Some demand-side factors that hinder access to
effective treatment include: the community's poor percep-
tions of quality of care, their lack of trust in health provid-
ers, and their perception of the effectiveness of drugs
provided in government health facilities [28,49].
Perceptions of causes of illness and differences in biomed-
ical and traditional illness concepts can hinder prompt
access to effective treatment. For example, convulsions
may be a sign of severe malaria, but in some parts of
Kenya, they are associated with supernatural powers,
which require the use of traditional healers and therefore
not amenable to western pharmaceuticals [26,30]. While
people's understanding of malaria has improved over the
years, and the use of traditional healers for malaria treat-
ment has reportedly declined [11], such beliefs may limit
the acceptance of treatment regimes. Continuous educa-
tion and awareness creation of the causes and treatment of
malaria should be maintained.
Table 3: Percent of fevers first treated at various sources of treatment
Reference Informal Public formal Private formal Formal (not categorized)
48 7 38 N/A
[7] 47 N/A N/A 53
57 N/A N/A 43
[37] 33 30 9 N/A
[28] 47 N/A N/A 26
[26] 77 N/A N/A N/A
[27] 67 N/A N/A 38
[34] 12 74 15 33
[35] 38 32 24 N/A
[44] 65 N/A N/A N/A
[25] 86 9 6 25
[29] 85 17 N/A N/AMalaria Journal 2009, 8:243 http://www.malariajournal.com/content/8/1/243
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Table 4: Use and source of anti-malarials for treatment of fever
Reference % of fevers treated with anti-malarials % of fevers treated using first-line anti-malarial Source of anti-malarials
[7] (Children) 23 N/A Informal
[7] (Adults) 37 N/A Informal
[37] 31 N/A Formal & informal
[41] 28 11 Formal & informal
[45] 31 10 Formal
[43] 33 27 Formal & informal
[26]* 47 3 Informal
[9] 48 90 Informal
[31] 29 N/A Informal
[16] N/A 1 Formal
[29] 58 12 Formal & informal
[11] 65 22 Informal
[40] 91 67 Formal
77 55 Formal
N/A = information not available.
*Indicates the percentage of fevers given anti-malarials at home. Study does not include the percentage given anti-malarials at health facilities.
Table 5: Mean number of days taken before seeking treatment by source of treatment
Study Formal Informal General
[37] N/A N/A 2 *
[43] 2 N/A N/A
[27] 2 0-1 N/A
[31] 3 1
[29] N/A N/A 1
[12] 4 (private clinics and government dispensary) 2 N/A
9 (district hospital)
[26] 3 N/A N/A
*MedianMalaria Journal 2009, 8:243 http://www.malariajournal.com/content/8/1/243
Page 8 of 13
(page number not for citation purposes)
Perceptions of illness severity and duration of illness may
prolong the period between treatment and onset of symp-
toms. The longer the period of illness, the more likely that
the caretaker or patient will seek treatment
[24,26,30,43,50]. People tend to adopt a wait-and-see
attitude when symptoms are perceived as less severe, only
seeking treatment when symptoms persist. Fever among
children prompts quicker action, which explains why a
large proportion of fevers were treated either at home or
at a health facility [18,24,26,51]. Care-seeking was also
shown to differ between seasons due to changes in cash
availability and perceptions of illness severity between
wet and dry seasons [11,18]. Cultural factors, too, have
been shown to influence timing of treatment. Women
have limited power to make decisions, while men control
resources, making it difficult for mothers to seek prompt
treatment for their ill children [26,43].
Communities' perceptions of different types of treatment
may hinder prompt access to the most effective treatment.
In Bungoma district, the community believed that SP was
too strong for children under one year and therefore
opted to buy alternative, but ineffective medicines, to pro-
tect children from the perceived strong effects of the drug
[52]. In Kilifi district, uptake of SP was constrained by
widely held beliefs within the community that chloro-
quine was still effective [8]. Elsewhere, health workers
reported that they continued to prescribe SP and amodi-
aquine because patients demanded familiar drugs [53].
Effective treatment can also be influenced by simplicity of
drug regimen, which is associated with higher levels of
treatment adherence. In Kilifi district, only about 10 per-
cent of people who purchased amodiaquine from shops
took the drug appropriately [8]; but the introduction of SP
resulted in higher rates of appropriate medicine use, a fac-
tor partly attributed to SP's simpler single-dose regimen.
Ability to meet the costs associated with a particular treat-
ment is an important factor influencing access and choice
of treatment. Even where malaria treatment is supposedly
free (in government health facilities), individuals still
incur costs, such as transport and laboratory services [17].
People often start with a cheaper treatment, then choose a
more expensive option as the illness persists or when
funds become available [24,26]. In agricultural communi-
ties, the seasonality of cash income may prevent house-
holds from seeking treatment on time [18].
Supply-side determinants
Supply-side determinants refer to health system factors
that deter people from obtaining appropriate treatment.
The degree to which services are available and acceptable
to the population plays a critical role in ensuring prompt
access to effective treatment.
Distance from health facilities is a critical factor influenc-
ing the use of the formal health care sector [18,27,33,54].
In Baringo district, 74 percent of households reported that
public health facilities were close to where they lived,
which was the main reason why they chose the formal sec-
tor as the first source of malaria treatment [33]. In many
areas in Kenya, however, the distribution of public health
care facilities is poor. Noor et al noted a reduction in the
number of patients using formal health services as their
distance from health facilities increased [54], while one
study reported that one-third of patients who self-treated
said that they would have sought treatment from a health
facility if it were near [29]. Not surprisingly, urban resi-
dents have better access to formal health care services than
their rural counterparts [26,55].
Another supply factor hindering access is availability of
medicines. Often, public health facilities do not have the
recommended anti-malarials in stock. Lack of medicines
in the formal sector contributes to people buying drugs
OTC, where the quality of drugs is less controlled and
information on dosage is not often provided. Health
workers and community members reported that public
health facilities suffered from chronic drug shortages due
to delays in drugs deliveries from the central level and the
failure to adjust drug quantities to suit seasonal fluctua-
tions in disease burden [17]. However, health workers did
not always prescribe the appropriate anti-malarials to
patients, even when the drugs were in stock [17,37,39]
Failure to prescribe the recommended medicines has been
shown in a recent study exploring prescribing practices
following the change of treatment policy from SP to AL. A
low level of prescriptions of the nationally recommended
drug was reported. Only 26 percent of children needing
treatment with AL according to national guidelines
received a prescription for this drug; 39 percent received
amodiaquine; four percent received SP; eight percent
received other anti-malarials; and 23 percent left the facil-
ity without any anti-malarials prescribed, although their
symptoms indicated the need for anti-malarials [37]. In
cases where AL was prescribed, dosages were more likely
to be correct compared to the more common drugs of
amodiaquine and SP [39,56]. The authors highlighted the
need for more case-management interventions--including
training and supervision--to ensure that all febrile chil-
dren receive the treatment as recommended by the
national guidelines. However, they noted that the short
time between policy implementation and the study did
not allow for any conclusions regarding supply of AL in
government facilities.
A follow-up study exploring why health workers did not
prescribe AL, despite the drug being in stock at the health
facilities, identified various reasons for non-adherence toMalaria Journal 2009, 8:243 http://www.malariajournal.com/content/8/1/243
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the treatment guidelines, most of which were related to
health workers responding to general health system weak-
nesses [53]: (1) insufficient supply of AL raised fears of
stock-outs if health workers prescribed it to all deserving
cases; (2) although AL was provided for free, it was con-
sidered expensive resulting to health workers assessing
which cases deserved to receive the drug; (3) continuous
supply of amodiaquine to health facilities after the policy
change, which led to health workers' confusion about pre-
scribing it; (4) lack of follow-up supervision after training;
(5) staff shortages and a high workload; (6) patients' pref-
erences for SP over AL because of its simple dosage and;
(7) cumbersome guidelines and contradictory training
messages that confused health workers.
Other supply factors are around quality of medicines. A
large number of unregistered and substandard pharma-
ceuticals circulate in the Kenyan market. An audit of 880
retailers (drug shops and pharmacies) identified 215 anti-
malarial brands in circulation in 2002 [48]. Of these, only
half of the SP and amodiaquine drugs were registered with
the Pharmacy and Poisons Board (PPB). Unregistered
drugs pose a danger to treatment because their safety, effi-
cacy, and quality cannot be guaranteed. Amodiaquine was
the most widely available anti-malarial in the retail sector,
despite being a prescription-only medication, while SP,
the first-line drug at the time of the survey, was only avail-
able in 29 percent of the outlets. The authors argued that
although a lack of regulatory enforcement in Kenya's drug
sector may be responsible for the pattern observed in the
retail market, limited community awareness of the treat-
ment policy may have contributed to the market for non-
recommended drugs. In addition, a wide range of prod-
ucts available to the community can create brand confu-
sion, which may lead to unintentional repeated doses of
the same drugs.
Policy-level determinants
Policy-level determinants can result at the national and
local levels, related to changing the first-line drug, staffing,
or financing public health facilities. Policy complexities
and unclear messages can undermine the potential of a
well-intended policy to promote quality case manage-
ment. A change in drug policy faces many challenges from
both the supply and demand perspective [8].
The challenges of changing drug policy in Kenya are well
documented. Adequate preparations, ensuring that phar-
maceutical industries are engaged in the discussion
regarding policy change during the initial stages to enable
them plan and adjust their manufacturing strategies in
line with the new policy to assure product availability, are
some of the factors that can promote smooth policy tran-
sition [57]. A policy aimed at exempting malaria patients
from paying for treatment at public health facilities in
Kenya has had limited impact [17]. While this policy aims
to reduce barriers to access for malaria patients by reduc-
ing costs, health workers expressed concerns about the
practicalities of implementing it. In settings where malaria
is the main cause of morbidity, facility managers reported
that exempting malaria patients from paying facility regis-
tration fees would lead to loss in revenue. Some facilities
opened privately operated laboratories, and health work-
ers have been reported as reluctant to prescribe AL before
the patient takes a parasite test. While laboratory services
are essential for identifying malaria, particularly among
older children and adults, having privately owned labora-
tories in health centers and dispensaries increases costs to
households and thus barriers to access.
As mentioned previously, home treatment increases the
proportion of ill individuals receiving anti-malarials
promptly, but the change in treatment policy to ACT may
affect the effectiveness of the anti-malarials that people
buy and take at home. ACT is not currently available in the
informal sector, which was an important source of anti-
malarials before the policy change, and amodiaquine
remains on the shelves as an alternative to those seeking
treatment from the informal sector. In an effort to stem
the circulation of ineffective anti-malarial monotherapies
in the market, the PPB issued a circular to local manufac-
turers and importers of these products to stop the manu-
facturer and importation of ineffective anti-malarial
monotherapies by end of March 2008. The extent to
which this was implemented is not clear.
Discussion
Self-treatment using OTC drugs will remain a norm in
household treatment for malaria. All studies in this
review, except for one, identified use of OTC drugs as the
most common first action. Self-treatment for malaria has
been reported in many parts of sub-Saharan Africa [58-
62], and various interventions have been put in place to
promote appropriate use of anti-malarials purchased
through the informal sector [7-9]. Shopkeepers training
interventions have been shown to be effective in terms of
costs and in reducing inappropriate use of anti-malarials
[6-9]. Nevertheless, controlling the quality of anti-malari-
als sold in the retail sector is difficult due to the heteroge-
neity of the shops selling OTC drugs, clients demands and
the profit maximization goal that defines the existence of
the private sector [63]. Currently, the informal sector
(shops and community health workers) are not allowed
to sell AL, although the same are available in the formal
retail sector (registered pharmacies). To improve access to
effective anti-malarials, AL should be made available
through the informal retail sector. Currently, the DOMC
is considering introducing AL for the home management
of malaria. Such an approach should be accompanied by
appropriate training programmes, an educative socialMalaria Journal 2009, 8:243 http://www.malariajournal.com/content/8/1/243
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marketing campaign to promote awareness of the new
drugs, and should be well designed to meet communities'
needs.
Often the drugs bought to treat malaria through OTC are
inappropriate and antipyretics remain the most widely
purchased drugs to treat malaria. Even with the treatment
policy change from SP to AL, the review identified amodi-
aquine as the main type of anti-malarial bought from the
informal sector, in addition to being prescribed widely by
health workers [44,48,64]. Some anti-malarials available
in the market are substandard or counterfeit [9,48,65],
which is particularly worrying, because substandard drugs
not only endanger lives, but they also jeopardize future
malaria treatment strategies. Poor enforcement of phar-
maceutical sector regulations can be a major threat to anti-
malarial effectiveness and provide a gateway to drug
resistance. Controlling the quality of anti-malarials pro-
vided through the private sector remains a challenge for
Kenya's drug regulatory agency. Nevertheless, it is impor-
tant to ensure that anti-malarials available in the market
are not only registered and meet the required standards,
but that monitoring is done to ensure safety, quality and
efficacy post-registration.
When people access the appropriate anti-malarials, poor
adherence to dosage is common. Although the review did
not identify any study that investigated adherence to AL in
Kenya, there are concerns that levels of non-adherence are
likely to be high and that this will not only result to treat-
ment failure, but will also encourage the development of
drug resistance [66].
Widespread appropriate use of anti-malarials will occur
only if significant efforts are directed towards educating
the community. Key messages that should be incorpo-
rated in education campaigns should include the benefits
of using the first-line recommended anti-malarials cor-
rectly, the dangers of incorrect dosage, and the types of
anti-malarials that are licensed by the PPB. Current strate-
gies, such as use of pre-packaged AL for weight, may help
increase adherence and improve communication between
health workers and patients. Since cost is a major barrier,
the government together with donors should consider
subsidizing AL provided through specific accredited retail
drug shops operating in malaria-endemic settings. This,
however, requires substantial resources and commitment
from the government and donors to ensure sustainability.
Initiatives to subsidize ACT are already in place (for exam-
ple, the Affordable Medicines Facility for malaria), but the
sustainability of their support to disease endemic coun-
tries, including Kenya, is uncertain. Other potential inter-
ventions include improving communication between
health workers and patients, for example through using
pictorial aids, when dispensing anti-malarials to ensure
that patients understand the correct dosage [67].
Although the review did not focus on access to preven-
tion, it is evident that campaigns to promote the use of
ITNs have achieved amazing results [4]. While prevention
plays an important role in reducing malaria morbidity
and mortality, interventions that address treatment are
equally important. In Kenya, information on ITNs use is
easily available through the media and one is likely to find
posters at health facilities and other areas advocating for
the use of ITNs. Similar efforts towards appropriate use of
anti-malarials are needed.
The review has shown that health workers do not always
prescribe the appropriate anti-malarials or doses to
patients [37,64,68]. Previous research on health worker
prescribing interventions has yielded mixed findings, with
some showing significant improvements in case-manage-
ment and others showing no effect at all. Regardless,
health workers require support to improve their prescrip-
tion practices, particularly when policy changes.
Health system factors play an important role in promot-
ing or hindering access to effective treatment. These inter-
related factors (for example, drug availability, provider
practices, quality of care and non-functional policies)
should be addressed as part of the system as a whole.
While the DOMC may address certain barriers of access, it
might not be in a position to influence providers' behav-
iour or address the deeper rooted problems associated
with high workload and poor remuneration. Improving
access to effective case management therefore, requires
that the Ministry of Health works together with the private
sector, the civil society and development partners towards
achieving a partnership that ensures the services provided
in both the public and private sector are in line with the
national guidelines.
Priorities for further research
To inform future policies and interventions various
research areas should be given priority. Information on
drug use patterns following policy change from SP to AL
is lacking. Only one study explored use of anti-malarials
following the implementation of the new policy, and
while this study provided useful insights into the range of
medicines used to treat malaria, it was conducted within
the first year of policy change (2006/2007). Considering
the supply of AL to the public sector was only initiated in
September 2006, additional data on the effect of the pol-
icy change over time are required. A survey exploring the
nature of the market for anti-malarials would comple-
ment household- level data on drug-use patterns.
Adherence to treatment is a topic that has not been
explored extensively. Adherence to ACT may pose a chal-
lenge, especially for the retail sector where business andMalaria Journal 2009, 8:243 http://www.malariajournal.com/content/8/1/243
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cost-saving strategies are key for the retailers and house-
holds respectively. Research to evaluate adherence to AL
would be useful for informing interventions aimed at pro-
moting effective use of anti-malarials.
Provider prescribing practices require further investiga-
tion. Further exploration of factors influencing providers'
behaviour and their perceptions regarding new treatment
guidelines would help inform the design of interventions
to improve diagnosis and prescribing practices.
Finally, more qualitative studies are needed to explore
and understand barriers to access. Unless the whys' and
hows' behind treatment-seeking patterns, irrational drug
use, and provider behaviour are well understood, effective
case management and achieving prompt access will
remain a challenge. Such studies should be designed to
explore all dimensions of access and how they interrelate
at the demand, supply, and policy levels.
Limitations of the review
There are several limitations of this review. First, attempts
to compare the evidence across studies were complicated
by differences in methodologies, populations of interest,
and sampling methods. Second, the majority of studies
were conducted in rural settings and while rural popula-
tions might face more barriers to access than their urban
counterparts, similar data on urban settings were lacking.
Third, access to malaria treatment was not a primary aim
for the majority of studies, and was thus not fully
explored. Finally, most studies were conducted at a time
when the recommended first-line anti-malarials in Kenya
were SP or chloroquine. Drug use patterns may be differ-
ent with the use of AL; information on drug use reported
in this review should be interpreted with caution.
Conclusion
Achieving the Abuja target on access to effective anti-
malarials within 24 to 48 hours remains a challenge for
Kenya. Additional efforts are needed to ensure that people
have access to the effective anti-malarials, and that high
levels of adherence to treatment are achieved. The govern-
ment, with support from donors, should invest ade-
quately in mechanisms that promote access to effective
treatment. Such approaches should focus on factors influ-
encing all dimensions of access and will require the coop-
eration of all stakeholders working in malaria control.
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